デフォルト表紙
市場調査レポート
商品コード
1417486

次世代がん診断市場レポート:2030年までの動向、予測、競合分析

Next Generation Cancer Diagnostics Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日: | 発行: Lucintel | ページ情報: 英文 150 - page report | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

次世代がん診断市場レポート:2030年までの動向、予測、競合分析
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

次世代がん診断の動向と予測

世界の次世代がん診断市場は、2024年から2030年までのCAGRが11.0%で、2030年までに推定179億米ドルに達すると予想されます。この市場の主な促進要因は、がん疾患の有病率の増加、効果的な予後予測やさまざまな種類のがんの早期発見の必要性、また、効果的な診断に対するニーズの高まりに対応するための新たなアプローチの創出に向けた重要な利害関係者の取り組みの高まりです。バイオマーカー開発、CTC解析、プロテオーム解析、エピジェネティック解析、遺伝子解析の各市場における機会により、世界の次世代がん診断市場の将来は有望視されています。

次世代がん診断市場の洞察

Lucintelは、がん治療における免疫療法や標的治療の普及により、効率的な治療モニタリングの需要が高まっているため、予測期間中も治療モニタリングが最大セグメントであり続けると予測しています。

北米は、堅固なヘルスケアシステムの存在と、がんの研究に強い注力をしているため、予測期間中も最大の地域であり続けると思われます。

よくある質問

Q1.市場規模は?

A1.世界次世代がん診断市場は2030年までに推定179億米ドルまで達すると予想されます。

Q2.市場の成長予測は?

A2.次世代がん診断市場は2024年から2030年にかけてCAGR 11.0%で成長すると予測されます。

Q3.市場の成長に影響を与える主な促進要因は?

A3.この市場の主な促進要因は、がん疾患の有病率の増加、効果的な予後予測やさまざまな種類のがんの早期発見の必要性、また、効果的な診断に対するニーズの高まりに対応するための新たなアプローチを生み出すための重要な利害関係者の取り組みの高まりです。

Q4.市場の主要セグメントは?

A4.バイオマーカー開発、CTC解析、プロテオーム解析、エピジェネティック解析、遺伝子解析の各市場における機会により、世界の次世代がん診断市場の将来は有望です。

Q5.市場の主要企業は?

A5.次世代がん診断の主要企業は以下の通り。

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Q6.今後、最大となる市場セグメントは?

A6.Lucintelは、がん治療における免疫療法や標的治療の普及により、効率的な治療モニタリングの需要が高まっているため、予測期間中も治療モニタリングが最大セグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は?

A7.北米は、堅固なヘルスケアシステムの存在と、がんの研究に強い注力をしているため、予測期間中も最大の地域であり続けると思われます。

Q8.レポートのカスタマイズは可能?

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の次世代がん診断市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向(2018~2023年)と予測(2024~2030年)
  • 世界の次世代がん診断市場動向(2018~2023年)と予測(2024~2030年)
  • がんの種類別の世界の次世代がん診断市場
    • 肺がん
    • 乳がん
    • 結腸直腸がん
    • 子宮頸がん
    • その他
  • 技術別の世界の次世代がん診断市場
    • 次世代シーケンス
    • 定量PCRと多重
    • ラボオンチップと逆転写PCR
    • タンパク質マイクロアレイ
    • DNAマイクロアレイ
  • 機能別の世界の次世代がん診断市場
    • 治療モニタリング
    • コンパニオン診断
    • 予後
    • がん検診
    • リスク分析
  • アプリケーション別の世界の次世代がん診断市場
    • バイオマーカーの開発
    • CTC分析
    • プロテオーム解析
    • エピジェネティック解析
    • 遺伝子解析
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の次世代がん診断市場
  • 北米の次世代がん診断市場
  • 欧州の次世代がん診断市場
  • アジア太平洋の次世代がん診断市場
  • その他地域の次世代がん診断市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • がんの種類別の世界の次世代がん診断市場の成長機会
    • 技術別の世界の次世代がん診断市場の成長機会
    • 機能別の世界の次世代がん診断市場の成長機会
    • アプリケーション別の世界の次世代がん診断市場の成長機会
    • 地域別の世界の次世代がん診断市場の成長機会
  • 世界の次世代がん診断市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の次世代がん診断市場の能力拡大
    • 世界の次世代がん診断市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare
目次

Next Generation Cancer Diagnostics Trends and Forecast

The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets. The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.

A more than 150-page report is developed to help in your business decisions.

Next Generation Cancer Diagnostics by Segment

The study includes a forecast for the global next generation cancer diagnostics by cancer type, technology, function, application, and region.

Next Generation Cancer Diagnostics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others

Next Generation Cancer Diagnostics Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Next-Generation Sequencing
  • qPCR & Multiplexing
  • Lab-On-A-Chip & Reverse Transcriptase-PCR
  • Protein Microarrays
  • DNA Microarrays

Next Generation Cancer Diagnostics Market by Function [Shipment Analysis by Value from 2018 to 2030]:

  • Therapeutic Monitoring
  • Companion Diagnostics
  • Prognostics
  • Cancer Screening
  • Risk Analysis

Next Generation Cancer Diagnostics Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Biomarker Development
  • CTC Analysis
  • Proteomic Analysis
  • Epigenetic Analysis
  • Genetic Analysis
  • Others

Next Generation Cancer Diagnostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Next Generation Cancer Diagnostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies next generation cancer diagnostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the next generation cancer diagnostics companies profiled in this report include-

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Next Generation Cancer Diagnostics Market Insights

Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.

North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.

Features of the Global Next Generation Cancer Diagnostics Market

Market Size Estimates: Next generation cancer diagnostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Next generation cancer diagnostics market size by various segments, such as by cancer type, technology, function, application, and region in terms of value ($B).

Regional Analysis: Next generation cancer diagnostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer type, technology, function, application, and regions for the next generation cancer diagnostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the next generation cancer diagnostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the next generation cancer diagnostics market size?

Answer: The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030.

Q2. What is the growth forecast for next generation cancer diagnostics market?

Answer: The global next generation cancer diagnostics market is expected to grow with a CAGR of 11.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the next generation cancer diagnostics market?

Answer: The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.

Q4. What are the major segments for next generation cancer diagnostics market?

Answer: The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets.

Q5. Who are the key next generation cancer diagnostics market companies?

Answer: Some of the key next generation cancer diagnostics companies are as follows.

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Q6. Which next generation cancer diagnostics market segment will be the largest in future?

Answer: Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.

Q7. In next generation cancer diagnostics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the next generation cancer diagnostics market by cancer type (lung cancer, breast cancer, colorectal cancer, cervical cancer, and others), technology (next-generation sequencing, qPCR & multiplexing, lab-on-a-chip & reverse transcriptase-PCR , protein microarrays, and DNA microarrays), function (therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, genetic analysis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Next Generation Cancer Diagnostics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Next Generation Cancer Diagnostics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Next Generation Cancer Diagnostics Market by Cancer Type
    • 3.3.1: Lung Cancer
    • 3.3.2: Breast Cancer
    • 3.3.3: Colorectal Cancer
    • 3.3.4: Cervical Cancer
    • 3.3.5: Others
  • 3.4: Global Next Generation Cancer Diagnostics Market by Technology
    • 3.4.1: Next-generation Sequencing
    • 3.4.2: qPCR & Multiplexing
    • 3.4.3: Lab-on-a-chip & Reverse Transcriptase-PCR
    • 3.4.4: Protein Microarrays
    • 3.4.5: DNA Microarrays
  • 3.5: Global Next Generation Cancer Diagnostics Market by Function
    • 3.5.1: Therapeutic Monitoring
    • 3.5.2: Companion Diagnostics
    • 3.5.3: Prognostics
    • 3.5.4: Cancer Screening
    • 3.5.5: Risk Analysis
  • 3.6: Global Next Generation Cancer Diagnostics Market by Application
    • 3.6.1: Biomarker Development
    • 3.6.2: CTC Analysis
    • 3.6.3: Proteomic Analysis
    • 3.6.4: Epigenetic Analysis
    • 3.6.5: Genetic Analysis
    • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Next Generation Cancer Diagnostics Market by Region
  • 4.2: North American Next Generation Cancer Diagnostics Market
    • 4.2.1: North American Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.2.2: North American Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.3: European Next Generation Cancer Diagnostics Market
    • 4.3.1: European Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.3.2: European Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.4: APAC Next Generation Cancer Diagnostics Market
    • 4.4.1: APAC Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.4.2: APAC Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.5: ROW Next Generation Cancer Diagnostics Market
    • 4.5.1: ROW Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.5.2: ROW Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Technology
    • 6.1.3: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Function
    • 6.1.4: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Application
    • 6.1.5: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Region
  • 6.2: Emerging Trends in the Global Next Generation Cancer Diagnostics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Next Generation Cancer Diagnostics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Next Generation Cancer Diagnostics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Janssen Pharmaceuticals
  • 7.2: Illumina
  • 7.3: Novartis
  • 7.4: F. Hoffmann-La Roche
  • 7.5: Koninklijke Philips
  • 7.6: QIAGEN
  • 7.7: Agilent Technologies
  • 7.8: Abbott
  • 7.9: Thermo Fisher Scientific
  • 7.10: GE HealthCare